AZ-SUPIMA/TEXTILEGENESIS
13.6.2022 10:02:09 CEST | Business Wire | Press release
Supima, the brand for American-grown Pima cotton, announces a strategic partnership with TextileGenesis™ to establish the new industry benchmark platform for authenticating cotton.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005099/en/
The Supima blockchain platform powered by TextileGenesis™ will digitally connect Supima’s comprehensive supply chain from the growers to the brand/retailers. Integrated with this digital platform, Supima’s technology partner Oritain™ will provide the forensic origin authentication for Supima cotton across the platform. The ability to independently validate the Supima content of products at every stage of the supply chain achieves unmatched authenticity and responsibility through the combination of forensic physical and digital authentication.
Since it was founded in 1954, SUPIMA® has been referred to as the “world’s finest cottons.” Today marks the next chapter in Supima’s ongoing leadership role in bringing the most trusted and robust verification solution to authentic premium fiber sourcing to the global fashion industry. SUPIMA® is fortunate to partner with brands and retailers that are leaders in transparency and responsible sourcing. This ground-breaking supply chain traceability platform will provide an underlying mechanism to collaborate with the partners in a transparent, and verifiable way.
TextileGenesis’ Fibercoin™ technology will be integrated into Supima’s licensing program and applied to all SUPIMA® branded fiber throughout the supply chain, creating a non-fungible digital token for every kilogram of Supima cotton that can be physically and forensically verified and authenticated by Supima from the farm through to the retail shelf. This pioneering effort for cotton sourcing sets a new standard for responsibility in the global textile industry and consumer marketplace. Supima is striving to bring deeper levels of authenticity and responsibility to cotton sourcing with greater support for equity and ubiquity for all partners in the supply chain.
“The Supima partnership with TextileGenesis provides for the very first time, undisputable proof of origin for consumer products all the way back to the fiber’s origin. This enables Supima’s partner brands to credibly claim advantages in terms of product quality and sustainability that are independently verifiable through both digital and forensic testing. There is no system like this for any other fiber. SUPIMA® partners will have the most authentic and trustworthy premium cotton source for all the current and future needs of luxury apparel and home textile products,” says Marc Lewkowitz, President and CEO of Supima.
“This collaboration is setting a new benchmark for the cotton and premium fiber’s industry, and paves a new path for the entire fashion eco-system. We are creatively combining three major innovations - digital-tokens based article-level traceability, forensic physical verification, and Supima brand-licensing - in a single integrated platform. It creates a new platinum standard in the industry for end-to-end traceability and physical verification,” says Amit Gautam, Founder and CEO of TextileGenesis.
ABOUT TEXTILEGENESIS
TextileGenesis is a market-leading traceability platform custom-built for the fashion and textile ecosystem. It has partnered with 40+ leading global brands to create fiber-to-retail traceability for sustainable, premium and certified materials. By the end of 2022, TextileGenesis will create traceability for 500 million+ units in the global fashion industry.
ABOUT SUPIMA
Supima is America’s luxury cotton: founded in 1954, the Supima brand, short for “Superior Pima,” designates an exclusive source of exceptional extra-long staple cotton responsibly grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color, indulgent softness, and durability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom